Jazz Pharmaceuticals (JAZZ) Shares Outstanding (Diluted Average) (2010 - 2026)

Jazz Pharmaceuticals has reported Shares Outstanding (Diluted Average) for 17 years, with the latest figure at $66.1 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding (Diluted Average) rose 8.36% year-over-year to $66.1 million; the trailing twelve-month figure through Mar 2026 stood at $66.1 million (up 8.36% YoY), and the FY2025 full-year result was $61.0 million, down 7.61% from the prior year.
• Shares Outstanding (Diluted Average) for Q1 2026 stood at $66.1 million, up from $61.0 million in the prior quarter.
• The five-year high for Shares Outstanding (Diluted Average) was $73.8 million in Q1 2023, with the low at $61.0 million in Q3 2025.
• Average Shares Outstanding (Diluted Average) over 5 years is $65.9 million, with a median of $63.4 million recorded in 2022.
• Year-over-year, Shares Outstanding (Diluted Average) grew 17.27% in 2023 and retreated 15.23% in 2024.
• Tracing JAZZ's Shares Outstanding (Diluted Average) over 5 years: stood at $62.5 million in 2022, then rose by 15.23% to $72.1 million in 2023, then retreated by 8.41% to $66.0 million in 2024, then declined by 7.61% to $61.0 million in 2025, then increased by 8.39% to $66.1 million in 2026.
• The last three Shares Outstanding (Diluted Average) figures came in at $66.1 million (Q1 2026), $61.0 million (Q4 2025), and $61.0 million (Q3 2025), per Business Quant data.

Peer Comparison